Nordea Investment Management AB Acquires 1,166 Shares of Medpace Holdings, Inc. $MEDP

Nordea Investment Management AB boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.9% during the 4th quarter, Holdings Channel reports. The firm owned 63,784 shares of the company’s stock after acquiring an additional 1,166 shares during the period. Nordea Investment Management AB’s holdings in Medpace were worth $35,930,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Fifth Third Wealth Advisors LLC increased its position in shares of Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the last quarter. BOKF NA boosted its holdings in shares of Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares during the last quarter. HighPoint Advisor Group LLC boosted its holdings in shares of Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after buying an additional 22 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares during the period. Finally, M&T Bank Corp grew its position in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 20.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on MEDP. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Truist Financial dropped their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Finally, Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a report on Friday, March 6th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Trading Up 1.0%

Medpace stock opened at $456.93 on Tuesday. The firm has a 50 day simple moving average of $506.24 and a 200 day simple moving average of $538.51. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a market capitalization of $12.97 billion, a price-to-earnings ratio of 29.86, a P/E/G ratio of 2.17 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period last year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.